Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-177

I am neither part of management nor on the board of Race, I am just a consultant and shareholder. I don't have the authority to give you an estimated timeline for when the updated review will be complete. All I can say is it will be released when it is complete and that it has the highest priority within Race.

Talks started with pharma before DCB arrived and have continued after he left. I really encourage everyone to take a look at the background of Pete Smith to understands that pharma engagement is not an area Race lacks in skills and experience.